Case number 1:23-cv-01019
Celgene Corporation et al v. Natco Pharma Limited > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 29, 2024 | 20 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,846,628 B2; US 11,571,436 B2. (Attachments: # 1 Consent Judgment - Natco Pharma Ltd.)(ceg) (Entered: 05/29/2024) (0) |
| May 29, 2024 | N/A | CASE CLOSED per Consent Judgment in LEAD case (C.A. 23-1008, D.I. 34). (ceg) (Entered: 05/29/2024) (0) |
| Feb 23, 2024 | N/A | Case associated with lead case: Create association to 1:23-cv-01008-JLH. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 1:23-cv-01008-JLH ONLY. (ceg) (Entered: 02/23/2024) (0) |
| Feb 23, 2024 | 19 | SCHEDULING AND CONSOLIDATION ORDER: Celgene Corporation v. Teva Pharmaceuticals, Inc., C.A. No. 1:23-cv-01008-JLH, and Celgene Corporation v. Natco Pharma Ltd., C.A. No. 1:23-cv-01019-JLH, are consolidated for all purposes up to and including trial. Joinder of Parties due by 8/23/2024. Amended Pleadings due by 8/23/2024. Status Report due by 10/23/2024. Fact Discovery completed by 4/4/2025. Expert Discovery due by 10/13/2025. Joint Claim Construction Brief due by 10/14/2024. A Markman Hearing is set for 1/9/2025 at 10:00 AM in Courtroom 6D before Judge Jennifer L. Hall. Proposed Pretrial Order due by 2/16/2026. A Pretrial Conference is set for 2/23/2026 at 03:00 PM in Courtroom 6D before Judge Jennifer L. Hall. A 3-day Bench Trial is set for 3/2/2026 at 09:30 AM in Courtroom 6D before Judge Jennifer L. Hall. (*See Order for details). Signed by Judge Jennifer L. Hall on 2/23/2024. Associated Cases: 1:23-cv-01008-JLH, 1:23-cv-01019-JLH(ceg) (Entered: 02/23/2024) (17) |
| Feb 21, 2024 | 18 | ORAL ORDER: The Rule 16(b) Conference scheduled for February 23, 2024 is CANCELLED. Ordered by Judge Jennifer L. Hall on 2/21/2024. Associated Cases: 1:23-cv-01008-JLH, 1:23-cv-01019-JLH(ceg) (Entered: 02/21/2024) (0) |
| Feb 20, 2024 | 17 | Letter to The Honorable Judge Jennifer L. Hall from Nathan R. Hoeschen regarding Rule 16 conference set for February 23, 2024. (Hoeschen, Nathan) Modified on 2/21/2024 (ceg). (Entered: 02/20/2024) (1) |
| Feb 13, 2024 | 16 | PROPOSED Scheduling Order, by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (Attachments: # 1 Letter to The Honorable Jennifer L. Hall)(Farnan, Michael) Modified on 2/13/2024 (ceg). (Entered: 02/13/2024) (0) |
| Jan 22, 2024 | N/A | ORAL ORDER: IT IS HEREBY ORDERED that the Scheduling Conference scheduled for February 5, 2024 is RESCHEDULED February 23, 2024 at 10:00 AM in Courtroom 6D before Judge Jennifer L. Hall. Ordered by Judge Jennifer L. Hall on 1/22/2024. Associated Cases: 1:23-cv-01008-JLH, 1:23-cv-01019-JLH(ceg) (Entered: 01/22/2024) (0) |
| Jan 18, 2024 | N/A | Pro Hac Vice Attorney Christopher J. Sorenson,Andrew O. Larsen,Jason M. Wiener for Natco Pharma Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk) (Entered: 01/18/2024) (0) |
| Jan 16, 2024 | N/A | Case Reassigned to Judge Jennifer L. Hall. Please include the initials of the Judge (JLH) after the case number on all documents filed. Associated Cases: 1:21-cv-01795-RGA, 1:23-cv-00699-RGA, 1:23-cv-01008-RGA, 1:23-cv-01019-RGA(nms) (Entered: 01/16/2024) (0) |
| Jan 11, 2024 | N/A | SO ORDERED, re 12 MOTION for Pro Hac Vice Appearance of Attorney Christopher J. Sorenson, filed by Natco Pharma Limited, 13 MOTION for Pro Hac Vice Appearance of Attorney Andrew O. Larson, filed by Natco Pharma Limited, and 14 MOTION for Pro Hac Vice Appearance of Attorney Jason Wiener, filed by Natco Pharma Limited. Signed by Judge Richard G. Andrews on 1/11/2024. (nms) (Entered: 01/11/2024) (0) |
| Jan 11, 2024 | 15 | Pro Hac Vice Fee - Credit Card Payment received for Christopher J. Sorenson, Andrew O. Larsen, and Jason Wiener. ( re 12 MOTION for Pro Hac Vice Appearance of Attorney Christopher J. Sorenson, 13 MOTION for Pro Hac Vice Appearance of Attorney Andrew O. Larson, 14 MOTION for Pro Hac Vice Appearance of Attorney Jason Wiener )( Payment of $ 150, receipt number ADEDC-4312498).(Green, James) (Entered: 01/11/2024) (0) |
| Jan 11, 2024 | 14 | MOTION for Pro Hac Vice Appearance of Attorney Jason Wiener - filed by Natco Pharma Limited. (Green, James) (Entered: 01/11/2024) (2) |
| Jan 11, 2024 | 13 | MOTION for Pro Hac Vice Appearance of Attorney Andrew O. Larson - filed by Natco Pharma Limited. (Green, James) (Entered: 01/11/2024) (2) |
| Jan 11, 2024 | 12 | MOTION for Pro Hac Vice Appearance of Attorney Christopher J. Sorenson - filed by Natco Pharma Limited. (Green, James) (Entered: 01/11/2024) (2) |
| Jan 2, 2024 | 11 | Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 2/5/2024, at 2:00 PM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 1/2/2024. (nms) (Entered: 01/02/2024) (1) |
| Dec 20, 2023 | 10 | ANSWER to 1 Complaint and Affirmative Defenses, by Natco Pharma Limited.(Green, James) Modified on 12/20/2023 (nms). (Entered: 12/20/2023) (22) |
| Nov 14, 2023 | N/A | SO ORDERED, re 9 UNOPPOSED Motion to Extend Time to Respond to Complaint (*Reset Answer Deadlines: Natco Pharma Limited answer due 12/20/2023). Signed by Judge Richard G. Andrews on 11/14/2023. (nms) (Entered: 11/14/2023) (0) |
| Nov 14, 2023 | 9 | UNOPPOSED Motion to Extend Time to Respond to Complaint - filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (Attachments: # 1 Proposed Order)(Farnan, Michael) Modified on 11/14/2023 (nms). (Entered: 11/14/2023) (0) |
| Sep 27, 2023 | N/A | Pro Hac Vice Attorney David Mlaver for Celgene Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:23-cv-01008-RGA, 1:23-cv-01019-RGA(mpb) (Entered: 09/27/2023) (0) |
| Sep 27, 2023 | N/A | Pro Hac Vice Attorney Heather M. Petruzzi, Amy K. Wigmore, Gerard A. Salvatore, Nora Q.E. Passamaneck, Andrew J. Danford, and Li-tsung A. Chen for Celgene Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:23-cv-01008-RGA, 1:23-cv-01019-RGA(mpb) (Entered: 09/27/2023) (0) |
| Sep 20, 2023 | N/A | SO ORDERED, re 8 MOTION for Pro Hac Vice Appearance of Attorney Amy K. Wigmore, Heather M. Petruzzi, Andrew J. Danford, Nora Q.E. Passamaneck, David Mlaver, Gerard A. Salvatore, and Li-tsung Alyssa Chen, filed by Celgene Corporation, Celgene International Sarl, Bristol-Myers Squibb Company. Signed by Judge Richard G. Andrews on 9/20/2023. (nms) (Entered: 09/20/2023) (0) |
| Sep 20, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 09/20/2023) (0) |
| Sep 19, 2023 | 8 | MOTION for Pro Hac Vice Appearance of Attorney Amy K. Wigmore, Heather M. Petruzzi, Andrew J. Danford, Nora Q.E. Passamaneck, David Mlaver, Gerard A. Salvatore, and Li-tsung Alyssa Chen - filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (Farnan, Michael) (Entered: 09/19/2023) (9) |
| Sep 19, 2023 | 7 | WAIVER OF SERVICE returned executed by Celgene Corporation, Bristol-Myers Squibb Company, Celgene International Sarl: For Natco Pharma Limited waiver sent on 9/19/2023, answer due 11/20/2023. (Farnan, Michael) (Entered: 09/19/2023) (1) |
| Sep 18, 2023 | 6 | Summons Issued as to Natco Pharma Limited on 9/19/2023. (twk) (Entered: 09/19/2023) (2) |
| Sep 18, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Celgene Corporation for Celgene International Sarl; Corporate Parent Bristol-Myers Squibb Company for Celgene Corporation filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (twk) (Entered: 09/19/2023) (2) |
| Sep 18, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,846,628 B2; US 11,571,436 B2. (twk) (Entered: 09/19/2023) (1) |
| Sep 18, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: August 28, 2023. Date of Expiration of Patent: June 3, 2030 (U.S. Patent No. 8,846,628); May 14, 2029 (U.S. Patent No. 11,571,436). Thirty Month Stay Deadline: 2/28/2026. (twk) (Entered: 09/19/2023) (2) |
| Sep 18, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 09/19/2023) (3) |
| Sep 18, 2023 | 1 | Complaint* (1) |
